MPI für molekulare Genetik / Department of Human Molecular Genetics |
|Screening chromosomal aberrations by array comparative genomic hybridization in 80 patients with congenital hypothyroidism and thyroid dysgenesis.|
|Authors:||Thorwarth, A.; Mueller, I.; Biebermann, H.; Ropers, Hans-Hilger; Grueters, A.; Krude, H.; Ullmann, Reinhard|
|Date of Publication (YYYY-MM-DD):||2010-07-01|
|Title of Journal:||The Journal of Clinical Endocrinology & Metabolism|
|Journal Abbrev.:||J. Clin. Endocrinol. Metab.|
|Issue / Number:||7|
|Copyright:||© 2010 by The Endocrine Society|
|Review Status:||not specified|
|Abstract / Description:||Objective:
Congenital hypothyroidism occurs in 1:3500 live births and is therefore the most common congenital endocrine disorder. A spectrum of defective thyroid morphology, termed thyroid dysgenesis (TD), represents 80% of permanent congenital hypothyroidism cases. Although several candidate genes have been implicated in thyroid development, comprehensive screens failed to detect mutation carriers in a significant number of patients with nonsyndromic TD. Due to the sporadic occurrence of TD, de novo chromosomal rearrangements are conceivably representing one of the molecular mechanisms participating in its etiology.
The introduction of array comparative genomic hybridization (CGH) has provided the ability to map DNA copy number variations (CNVs) genome wide with high resolution. We performed an array CGH screen of 80 TD patients to determine the role of CNVs in the etiology of the disease.
We identified novel CNVs that have not been described as frequent variations in the healthy population in 8.75% of all patients. These CNVs exclusively affected patients with athyreosis or thyroid hypoplasia and were nonrecurrent, and the regions flanking the CNVs were not enriched for segmental duplications.
The high rate of chromosomal changes in TD argues for an involvement of CNVs in the etiology of this disease. Yet the lack of recurrent aberrations suggests that the genetic causes of TD are heterogenous and not restricted to specific genomic hot spots. Thus, future studies may have to shift the focus from singling out specific genes to the identification of deregulated pathways as the underlying cause of the disease.
|Comment of the Author/Creator:||Address all correspondence and requests for reprints to: Prof. Dr. H. Krude, M.D. (patient cohort), Charité University Medicine Berlin, Institute for Experimental Pediatric Endocrinology, Augustenburger Platz 1, 13353 Berlin, Germany. E-mail: email@example.com. Or Dr. R. Ullmann (array CGH), Max Planck Institute for Molecular Genetics, Ihnestrasse 63-73, 14195 Berlin, Germany. E-mail: firstname.lastname@example.org.|
|External Publication Status:||published|
|Communicated by:||Hans-Hilger Ropers|
|Affiliations:||MPI für molekulare Genetik|
|External Affiliations:||1.Institute for Experimental Pediatric Endocrinology (A.T., H.B., A.G., H.K.), Charite University Medicine, 13353 Berlin, Germany.|
The scope and number of records on eDoc is subject
to the collection policies defined by each institute
- see "info" button in the collection browse view.